Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

470 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.
De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Skoneczna I, Marreaud S, de Wit R, Sylvester R. De Santis M, et al. Among authors: de wit r. J Clin Oncol. 2009 Nov 20;27(33):5634-9. doi: 10.1200/JCO.2008.21.4924. Epub 2009 Sep 28. J Clin Oncol. 2009. PMID: 19786668 Free PMC article. Clinical Trial.
Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group.
de Wit R, Stoter G, Sleijfer DT, Kaye SB, de Mulder PH, ten Bokkel Huinink WW, Spaander PJ, de Pauw M, Sylvester R. de Wit R, et al. Among authors: de pauw m, de mulder ph. Br J Cancer. 1995 Jun;71(6):1311-4. doi: 10.1038/bjc.1995.254. Br J Cancer. 1995. PMID: 7540039 Free PMC article. Clinical Trial.
Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
de Wit R, Sylvester R, Tsitsa C, de Mulder PH, Sleyfer DT, ten Bokkel Huinink WW, Kaye SB, van Oosterom AT, Boven E, Vermeylen K, Stoter G. de Wit R, et al. Among authors: de mulder ph. Br J Cancer. 1997;75(3):432-5. doi: 10.1038/bjc.1997.71. Br J Cancer. 1997. PMID: 9020492 Free PMC article. Clinical Trial.
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.
de Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW, Rea LA, Collette L, Sylvester R. de Wit R, et al. J Clin Oncol. 1997 May;15(5):1837-43. doi: 10.1200/JCO.1997.15.5.1837. J Clin Oncol. 1997. PMID: 9164193 Clinical Trial.
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
Horwich A, Sleijfer DT, Fosså SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, de Wit R, de Mulder PH, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP. Horwich A, et al. Among authors: de wit r, de mulder ph. J Clin Oncol. 1997 May;15(5):1844-52. doi: 10.1200/JCO.1997.15.5.1844. J Clin Oncol. 1997. PMID: 9164194 Free article. Clinical Trial.
Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
Steward WP, von Pawel J, Gatzemeier U, Woll P, Thatcher N, Koschel G, Clancy L, Verweij J, de Wit R, Pfeifer W, Fennelly J, von Eiff M, Frisch J. Steward WP, et al. Among authors: de wit r. J Clin Oncol. 1998 Feb;16(2):642-50. doi: 10.1200/JCO.1998.16.2.642. J Clin Oncol. 1998. PMID: 9469353 Clinical Trial.
Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.
Kaye SB, Mead GM, Fossa S, Cullen M, deWit R, Bodrogi I, van Groeningen C, Sylvester R, Collette L, Stenning S, De Prijck L, Lallemand E, deMulder P. Kaye SB, et al. J Clin Oncol. 1998 Feb;16(2):692-701. doi: 10.1200/JCO.1998.16.2.692. J Clin Oncol. 1998. PMID: 9469359 Clinical Trial.
Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.
Fosså SD, Kaye SB, Mead GM, Cullen M, de Wit R, Bodrogi I, van Groeningen CJ, De Mulder PH, Stenning S, Lallemand E, De Prijck L, Collette L. Fosså SD, et al. Among authors: de wit r, de prijck l, de mulder ph. J Clin Oncol. 1998 Feb;16(2):716-24. doi: 10.1200/JCO.1998.16.2.716. J Clin Oncol. 1998. PMID: 9469362 Clinical Trial.
Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer.
de Wit R, Stoter G, Sleijfer DT, Neijt JP, ten Bokkel Huinink WW, de Prijck L, Collette L, Sylvester R. de Wit R, et al. Among authors: de prijck l. Br J Cancer. 1998 Sep;78(6):828-32. doi: 10.1038/bjc.1998.587. Br J Cancer. 1998. PMID: 9743309 Free PMC article. Clinical Trial.
470 results